Fig. 6.

Survival curve in the patients with metastatic lesions (M1) based on the treatment effects. a Progression-free survival curve in M1 patients treated with IFN-α alone. One patient of IFN-α: CR-PR group progressed gradually into progressive disease (PD) after partial response (PR), but continued IFN-α monotherapy. Median survival time in IFN-α: SD-PD group is 16.7 months. Survival time of IFN-α: CR-PR group does not reach. b Progression-free survival curve in M1 patients after combination therapy with IFN-α plus sorafenib. Median survival time in IFN-α + Sor: SD-PD group is 4.3 months. Survival time of IFN-α + Sor: CR-PR group does not reach. c Overall survival curve in M1 patients treated with IFN-α with/without sorafenib. Median survival time in IFN-α + Sor: SD-PD group is 15.6 months. Survival time of IFN-α ± Sor: CR-PR group does not reach. P value was analyzed by log-rank test